Group 1 - The core viewpoint of the article highlights the approval of Novartis' innovative drug, Noreda® (Acrylamide Hydrochloride Tablets), as the first non-immunosuppressive therapy for IgA nephropathy in China, addressing a significant treatment gap in this area [1][3] - IgA nephropathy is prevalent among young adults in China, particularly those aged 20 to 30, with a high risk of progression to kidney failure if not effectively managed [1] - The drug is expected to be used in conjunction with existing standard treatments, providing new options for long-term disease management for patients [1][3] Group 2 - JD Health will leverage its robust pharmaceutical health service ecosystem to deepen its focus on chronic disease management, particularly in kidney diseases [1] - The collaboration with a leading global pharmaceutical company like Novartis aims to introduce cutting-edge therapeutic drugs and comprehensive digital health management solutions for patients [1][3] - JD Health's capabilities in supply chain fulfillment and professional pharmacist services will enhance the accessibility and precision of innovative drugs reaching patients nationwide [3]

Core Insights - Novartis has launched its innovative drug, Noreda (Acrylamide Hydrochloride Tablets), on JD Health, marking it as the first approved non-immunological therapy for adult patients with primary IgA nephropathy in China [1][2] - The drug is a highly selective endothelin A (ETA) receptor antagonist, filling a significant gap in non-hormonal basic treatments for this condition [2] Group 1 - Noreda is designed to reduce the risk of rapid disease progression in IgA nephropathy patients, which is prevalent among young adults aged 20 to 30 in China [1] - Clinical studies indicate that approximately 50% of IgA nephropathy patients with persistent proteinuria may progress to renal failure within 10 to 20 years if not effectively managed [1] - The collaboration between JD Health and Novartis aims to enhance the accessibility and precision of innovative treatments for patients nationwide [1][2] Group 2 - JD Health plans to deepen its focus on chronic disease management, particularly in kidney diseases, by leveraging its robust healthcare service ecosystem [2] - The introduction of Noreda is expected to provide new options for long-term disease management alongside existing standard treatments [2] - JD Health aims to offer comprehensive digital health management solutions for patients, improving the quality of life for those with kidney diseases and other chronic conditions [2]